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Abstract
Hepatitis C virus (HCV) is a major causative agent of chronic hepatitis and hepatocellular
carcinoma worldwide and thus poses a significant public health threat. A hallmark of HCV
infection is the extraordinary ability of the virus to persist in a majority of infected people. Innate
immune responses represent the front line of defense of the human body against HCV
immediately after infection. They also play a crucial role in orchestrating subsequent HCV-
specific adaptive immunity that is pivotal for viral clearance. Accumulating evidence suggests that
the host has evolved multifaceted innate immune mechanisms to sense HCV infection and elicit
defense responses, while HCV has developed elaborate strategies to circumvent many of these.
Defining the interplay of HCV with host innate immunity reveals mechanistic insights into
hepatitis C pathogenesis and informs approaches to therapy. In this review, we summarize recent
advances in understanding innate immune responses to HCV infection, focusing on induction and
effector mechanisms of the interferon antiviral response as well as the evasion strategies of HCV.
1. Introduction
Infection with hepatitis C virus (HCV) is a significant cause of chronic hepatitis globally. It
is estimated that 130 million people are infected with HCV, and that the number of newly
infected individuals is on the rise. HCV has a restricted host range, infecting only humans
and chimpanzees. The virus replicates predominantly in hepatocytes, which constitute 80%
of the liver mass. HCV infection is usually subclinical and typically asymptomatic.
However, the virus replicates in the liver continuously and progressively, establishing life-
long, intrahepatic persistent infection in up to 70% of infected individuals, putting patients at
risk for cirrhosis and hepatocellular carcinoma. As such, HCV-associated end-stage liver
disease represents the leading indication for liver transplantation (95). There is no vaccine
available to prevent HCV infection. Until recently, pegylated interferon (IFN)-α2a or -α2b
plus ribavirin (PegIFN/RBV) was the standard-of-care treatment for chronic hepatitis C, but
eliminated the virus in no more than 50% of those infected with genotype 1 virus who
received the therapy. Various direct-acting antiviral drugs (DAAs) are in the development
pipeline and have demonstrated promising efficacy in clinical trials. Of note, two viral
protease inhibitors have recently been approved by FDA for clinical use and have been
shown to improve the efficacy of PegIFN/RBV therapy in these difficult-to-cure patients.
However, because of rapid selection of resistant virus, these protease inhibitors must be
administered in combination with PegIFN/RBV (94). This 3-drug combination has recently
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become the standard-of-care in the U.S., but will likely be replaced in the future by IFN-
sparing drug combinations incorporating more potent DAAs.
HCV is a small, enveloped RNA virus classified within the family Flaviviridae. The virus
possesses a ∼10-kb long, positive-sense RNA genome packed with the viral capsid protein
(core) inside a 50∼60 nm enveloped virion. Its genome encodes a large polyprotein of about
3000 amino acids that is processed by a combination of host and viral proteases into 10
individual proteins. The structural proteins, core, envelope 1 (E1) and E2 are located in the
amino-terminal one-third, while the remaining carboxyl terminal two-thirds comprises the
nonstructural (NS) proteins, p7, NS2, NS3, NS4A, NS4B, NS5A and NS5B. Among these,
the NS3 to NS5B proteins are absolutely required for viral RNA replication (120). A
frameshift (F, a.k.a., ARF) protein may be expressed from the core-coding region as a result
of translation from an alternative reading frame, but its role in the HCV life cycle, if any, is
uncertain (19). The known functions of HCV proteins are shown in Fig. 1. Flanking the
HCV polyprotein-coding sequence are the 5′- and 3′-nontranslating regions (NTRs), which
contain complex secondary structures that serve as cis-replication signals interacting with
viral and host factors. The 5′-NTR also contains an internal ribosome entry site (IRES),
which directs the cap-independent translation of the HCV polyprotein (95, 120). HCV is
highly heterogeneous in its genomic sequence – it comprises 6 major genotypes and dozens
of subtypes that exhibit different geographical distribution and differential responses to
PegIFN/RBV therapy (40).
Since the identification of HCV in 1989, research on the virus has been impeded by a lack of
efficient cell culture systems and small convenient animal models. In 1997, replication of
the first infectious molecular clone of the H77 strain (genotype 1a) of HCV in the
chimpanzee model was described (88). The first HCV RNA replicon derived from the Con1
strain (genotype 1b) was established in hepatoma Huh-7 cells in 1999 (105). Complete
replication of HCV in cell culture became possible in 2005 (102, 175, 187), owing to
isolation of the unique, highly replication-competent JFH-1 strain (genotype 2a) from a
Japanese patient with fulminant hepatitis C (80). A workable infectious culture system based
on H77 has also been described (183), and minimal amounts of infectious virus have been
produced from Con1 RNA in cell culture (128), but both are less robust than JFH-1. With
these systems, a better picture of the HCV life cycle is emerging, details of which were
reviewed recently (103, 120). Briefly, following attachment, HCV enters host cells by
receptor-mediated endocytosis. Upon uncoating, the incoming messenger-sense viral RNA
serves as the template for translation of HCV proteins via the IRES in 5′NTR. The NS
proteins, along with the genomic RNA template, assemble viral replication complexes in
cytoplasmic vesicles that result from extensive membrane re-arrangements induced by
NS4B. Acting as the catalytic core of a large macromolecular replicase complex, the NS5B
polymerase then directs the transcription of the anti-sense HCV RNA strands, followed by
synthesis of nascent sense strands in an asymmetric fashion. As with many positive-stranded
RNA viruses (180), HCV RNA replication process generates double-stranded (ds) RNA
intermediates (165), which present a major viral pathogen associated molecular pattern
(PAMP) that is sensed by various innate immune sensors, known as pattern recognition
receptors (PRRs, see details in Section 3). The nascent messenger-sense strand HCV RNAs
can serve as templates for translation of more viral protein or synthesis of negative strand
RNAs, or can be packaged within new virions that exit the cells through a secretory pathway
that appears to usurp aspects of the lipoprotein secretion apparatus of the hepatocyte.
Antigen-specific adaptive T cell immunity plays an important role in determining the
outcome of acute HCV infection. The development of early, vigorous and multi-epitope
CD4+ and CD8+ T cell responses is crucial for HCV clearance (18, 118, 140). Because
adaptive immunity requires weeks and even months to develop, early host control of HCV
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infection relies on the innate immune response, an evolutionarily ancient, intrinsic set of
defenses that host cell use to combat invading pathogens immediately after infection. These
target invaders in an antigen-independent, but often pathogen class-specific fashion. Not
only does innate immunity buy time for the host to develop adaptive immunity, it is also
instrumental in shaping the latter. Apart from the participation of innate immune cells such
as natural killer (NK), NKT and dendritic cells (DCs) (40, 137), a major component of the
innate immune response to HCV infection is the induction of IFNs and inflammatory
cytokines and chemokines. The IFNs act directly against HCV replication in infected cells
and protect uninfected neighboring cells from infection by inducing the expression of
antiviral IFN-stimulated genes (ISGs). No less important, IFNs activate a variety of immune
effector cells important for HCV surveillance and clearance. Chemokines and inflammatory
cytokines are central to T cell homing to the liver in HCV infection (176, 185). Taken
together, IFNs and chemokines are critical mediators that bridge innate and adaptive
immunity, and their induction likely plays an important role in HCV pathogenesis and
infection outcome. Recent evidence suggests that HCV infection both induces and disrupts
signaling pathways leading to IFN and cytokine expression. In this review, we summarize
recent advances in host innate immunity to HCV infection, focusing on the induction and
effector mechanisms of the IFN-driven antiviral response as well as the evasion strategies
evolved by HCV.
2. Overview of the innate immune responses to HCV
A hallmark of the innate immune responses of mammalian hosts to viral infection is the
rapid induction of IFNs and cytokines. IFNs inhibit viral replication in infected cells and
establish an antiviral state in uninfected neighboring cells by inducing the expression of
ISGs with broad antiviral activities. IFNs also play an important role in activation of various
immune effector cells, thereby linking innate and adaptive immunity (16, 148). Pro-
inflammatory cytokines and chemokines regulate the maturation of innate and adaptive
immune cells and are crucial for their recruitment to the site of infection (16). There are 3
types of IFNs that are defined by the receptors they utilize. The type I IFNs comprise IFN-β
and a number of IFN-α subtypes. These can be produced by most cell types in the body and
act through an equally broadly-expressed receptor. Type II IFN includes only a single
molecule, IFN-γ, and its production is confined to NK cells and activated T cells. Type III
IFNs, the most recently identified group of IFNs, include 3 members, IL29 (IFN-λ.1),
IL28A (IFN-λ2) and IL28B (IFN-λ3) (16). The IFN-λs can be produced by many but not
all cell types, and target a receptor that has primarily an epithelial distribution (that includes
hepatocytes).
The IFNs activate downstream signaling pathways, known as Jak-Stat signaling, by binding
to and activating their class-specific cell surface receptors (16, 148). The type I IFN receptor
is composed of two subunits, IFNAR1 and IFNAR2, which are ubiquitously expressed in all
cell types. Engagement of type I IFNs triggers the hetero-dimerization of IFNAR1 and
IFNAR2, leading to the activation of intracellular Janus kinases, JAK1 and TYK2.
Subsequently, the JAKs phosphorylate the latent transcription factors, Stat1 and Stat2,
which then recruit IFN-regulatory factor (IRF) 9 to form a hetero- trimeric complex, IFN
stimulated gene factor-3 (ISGF3). ISGF3 moves to the nucleus where it binds to the IFN-
stimulated response element (ISRE) present in promoters of ISGs, thereby activating their
transcription. Several hundreds of genes are known to be transcriptionally-regulated by type
I IFNs, but the biological functions of most of these ISGs remain undefined. The type III
IFNs activate the same Jak-Stat pathway as type I IFNs, but do so through an entirely
different hetero-dimeric receptor comprised of IL28R1 and IL10R2. IL28R1 has a very
limited distribution, and is expressed primarily by epithelial cells as discussed above. For the
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most part, type I and type III IFNs induce similar sets of ISGs, although the kinetics of these
responses may differ.
Signaling induced by type II IFN, IFN-γ, is different from that of type I and III IFNs in
many ways. It utilizes a receptor comprised of IFNGR1 and IFNGR2 to activate JAK1 and
JAK2 kinases. This triggers the formation of a phosphorylated Stat1 homo-dimer, which
binds to a different element in target promoters known as the IFN--γ activated site (GAS).
Thus, the ISG profile induced by IFN-γ is different from those induced by type I and III
IFNs. It should be noted that human hepatocytes express functional receptors for all 3 IFN
types. Consistent with this, all three types of IFNs exhibit antiviral activity against HCV
replication in vitro (47, 58, 111, 139, 189).
Microarray analysis has demonstrated that HCV infection is generally associated with
induction of a strong ISG response in the liver in vivo (11, 158). In addition, the expression
of Intrahepatic chemokines such as the CCR5 ligands, RANTES, MIP-1α and MIP-1β, and
the CXCR3 ligand, IP-10, I-Tac and MIG is often elevated in hepatitis C, and the levels of
some of these correlate with the outcome of HCV infection or severity of liver inflammation
(64, 176, 185). However, the specific cellular sources of IFN(s) and cytokines/chemokines
in the HCV-infected liver are not known, and the signaling pathways responsible for their
induction are not defined. Apart from replicating in hepatocytes, circumstantial evidence
suggests that HCV may have a limited capacity to infect specific immune cell sets.
However, cell-culture derived JFH-1 virus does not infect any type of circulating immune
cells, including B and T lymphocytes, monocytes, macrophages and DCs (114). At the same
time, in vitro data suggest that human hepatocytes have the ability to induce type I and type
III IFNs and cytokines/chemokines (73, 96, 98, 178). Relatively little is known, however,
how they respond to HCV infection. A recent study showed that infection of primary human
fetal liver cells (HFLC) with HCV led to the induction of type III IFNs and ISGs with little
evidence of type I IFN expression, raising the possibility that type III IFNs may play an
important role in the innate antiviral responses to HCV (113). While this finding would be
consistent with the recent discovery in genome-wide association studies that IL28B gene
polymorphisms are associated with the outcome of HCV infection and Peg-IFN/RBV
therapy, the IL28B SNP genotype did not correlate with levels of IL29, IP-10 or I-Tac
expressed in these HCV-infected HFLC cultures (113), nor did it correlate with IL28A/B
expression levels in liver biopsies of hepatitis C patients (170). Exactly how the induction of
different IFNs, and SNPs near the IL28B gene contribute to innate immune responses to
HCV infection in the liver remains elusive. As discussed further below, high levels of ISG
expression within the liver correlate generally with poor response to Peg/IFN therapy.
With the exception of IFN-γ for which transcription is regulated differently, viral induction
of the type I and III IFNs as well as other cytokines shares overlapping regulatory
mechanisms, and is dependent on coordinated activation of the latent cytosolic transcription
factors, IRF3 and/or IRF7, and NF- κB(16), following signal transduction from upstream
PRRs (see Section 3). Among these, IRF3 and NF-κB are constitutively expressed, while
IRF7 is expressed at low levels except in plasmacytoid DCs (pDCs) and requires IFN
autocrine/paracrine signaling to increase its expression. Activation of IRF3 and IRF7
depends on specific phosphorylation within their C-terminal domains by the IRF3/7 kinases,
Tank binding kinase 1 (TBK1) or IKKε. This results in homo- or hetero-dimerization of
IRF3 and/or IRF7 and subsequent nuclear translocation to bind to target promoters. In
contrast, activation of NF-κB relies on phosphorylation and subsequent proteasomal
degradation of IκB, the repressor unit that normally sequesters NF-κB in the cytoplasm.
This is mediated by the classical IKK complex composed of IKKα, IKKβ and IKKγ. In
general, IFN-β and IFN-λ1 are transcriptionally controlled by IRF3, while transcription of
the IFN-αs and IFN-λ2/3 is more dependent upon IRF7 (122, 124, 149). Induction of the
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cytokines/chemokines, on the other hand, is due more to NF-κB activation. Very little is
known about the activation status of these different transcription factors in different cell
types within the HCV-infected liver.
3. PRRs and innate immune pathways sensing HCV infection
Upon infection of host cells, viruses present various types of PAMPs that are recognized as
“non-self” by the host. These PAMPs are engaged by different PRRs that trigger distinct
signaling pathways leading to production of IFNs and inflammatory cytokines and
chemokines. Depending on their subcellular localization, PRRs are classified into two
groups, i.e., the cytoplasmic retinoic inducible gene-I (RIG-I)-like receptors (RLRs) and the
membrane-bound, usually endosomal, Toll-like receptors (TLRs) (84). Although viral
proteins can be sensed by certain host PRRs, viral nucleic acids have distinct features and
represent the major PAMP that activates innate antiviral immunity. We discuss here the
PRRs and pathways that have been implicated in innate sensing of HCV infection by the
host (Fig. 2).
3.1. RLRs
The RLRs are a group of three cytosolic RNA helicases: RIG-I (a.k.a., DDX58), melanoma
differentiation associated gene 5 (MDA5, a.k.a., IFIH1 or helicard), and laboratory of
genetics and physiology 2 (LGP2, a.k.a., DHX58). They share a similar structure
composition, containing tandem caspase activation and recruitment (CARD) domains at the
N-terminus (except LGP2) that activate downstream signaling, a central helicase domain,
and a C-terminal domain (CTD) that plays a regulatory role (77). The RLRs are present in
an auto-repressed state with little activity in resting cells. During viral infection, the CTD of
RIG-I/MDA5 binds to its preferred ligand, resulting in a conformational change that exposes
the N-terminal CARDs, which can then interact with the CARD domain of mitochondrial
antiviral signaling protein (MAVS, a.k.a, Cardif, IPS-1 and VISA), the adaptor for RLRs.
Interestingly, MAVS was found to localize on both peroxisomes and mitochondrial outer
membrane (34, 150), which are platforms for downstream signaling for early and late ISG
expression, respectively. The peroxisome MAVS induces rapid, albeit temporary induction
of a small subset of ISGs through IRF1 and IRF3, independent of IFN induction, while
mitochondrial MAVS associates with TRAF3, leading to the activation of TBK1 or IKKε,
kinases that phosphorylate and activate IRF3/IRF7, resulting in a somewhat later, full-blown
IFN response. In addition, MAVS activates the classical IKK complex leading to NF-κB
activation, possibly with the participation of FADD and caspase 8/10 (84). Other evidence
suggests that the endoribonuclease, RNase L (see also in section 4.1), cleaves cellular and
viral RNAs and amplifies RLR signaling (110).
The RLR pathway functions in both somatic cells as well cells of the immune system,
except for pDCs in which the TLR7 pathway is dominant for sensing viral RNAs (see
Section 3.3). The RLRs are basally expressed at low levels; however they are strongly
induced by IFN stimulation or virus infection, providing a positive feedback mechanism of
innate immune signaling.
The PAMP for RIG-I has been defined as short, blunt-ended dsRNAs (<300 bp) or single-
stranded (ss) RNAs bearing 5′ triphosphates and rich in polyuridine runs (77, 107). Gene
knockout studies in mice have shown that RIG-I is essential for innate antiviral responses to
negative-strand RNA viruses, such as influenza and vesicular stomatitis virus, Sendai virus,
as well as flaviviruses, such as Japanese encephalititis virus, dengue virus and West Nile
virus (WNV)(46, 79, 106). The latter two viruses are also known to be sensed by MDA5
(see below). HCV RNA is also sensed by RIG-I in Huh-7 cells and in the liver of mice
transfected with synthetic RNA by hydrodynamic injection (141). One HCV PAMP for
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RIG-I was mapped to the poly-U/UC track RNA in 3′NTR, along with its 5′-end
triphosphate moiety (141, 172). Deletion of this sequence motif from HCV RNA diminished
its ability to activate RIG-I dependent IFN response when transfected into mice (141).
Huh-7.5 cells, which are derived from Huh-7 cells and highly permissive for HCV
replication, are defective for RIG-I signaling due to a lethal mutation in the RIG-I CARD.
Although other cellular factors are likely to contribute to the high permissiveness of Huh-7.5
cells, reconstitution of RIG-I rendered Huh-7.5 cells relatively non-permissive for HCV
replication (159). Thus, there are several lines of evidence supporting a role for RIG-I in
sensing and controlling HCV infection.
MDA5 preferentially recognizes long dsRNAs generated during infection with
picornaviruses such as EMCV, mengovirus and Theiler's virus, and high molecular mass
synthetic poly-I:C, a dsRNA surrogate (78, 79). Whether MDA5 serves as a PRR for HCV
infection is unclear, although two flaviviruses closely related to HCV, dengue virus and
West Nile virus, activate MDA5 in addition to RIG-I (46, 79, 106). Of note, both RIG-I and
MDA5 were identified in a recent ISG screen for antiviral effectors restricting HCV
replication in Huh-7.5 cells (145). Because transient expression of MDA5 by itself induces
greater IFN promoter activation than RIG-I (184), it is possible that the anti-HCV phenotype
may have been due to the IFN-inducing effect of MDA5 over-expression per se,
independent of MDA5 recognition of HCV dsRNA. Although there are differences in the
recognition of viral RNAs by RIG-I and MDA5, it is clear that there is considerable overlap.
Relatively little is known about the function of the third RLR, LGP2, in signaling. Studies in
knockout mice suggest that LGP2 plays a regulatory role for RIG-I/MDA5 recognition of
certain RNA viruses such as EMCV (144, 173). Because LGP2 is dispensable for cytokine
induction following stimulation of synthetic RNA ligands, it is postulated that LGP2 may
help strip off proteins from viral ribonucleoprotein complexes, allowing access of viral
RNAs to RIG-I/MDA5 (84). No information is available as to whether LGP2 contributes to
RLR sensing of HCV infection.
3.2. TLR3
Toll-like receptor (TLR)-3 was the first identified TLR that recognizes viral nucleic acids
(3). TLR3 is expressed in myeloid DCs (mDCs), macrophages, fibroblasts, epithelial cells,
hepatocytes and cells in the central nervous system and (96, 115, 178). A type I
transmembrane protein, TLR3 is comprised of an amino-terminal horse shoe-shaped
ectodomain that contains leucine rich repeats recognizing dsRNA, a transmembrane region,
and a cytosolic carboxy-terminal Toll-IL1 receptor homology (TIR) domain that activates
downstream signaling (84). TLR3 senses genomes of dsRNA viruses, dsRNAs derived from
replication intermediates of positive-strand RNA viruses, and overlapping bidirectional
transcripts of DNA viruses, as well as poly-I:C. A minimal length of 45 bp is required for
dsRNA to bind to a dimeric unit of two TLR3 ectodomains to trigger downstream signaling
(17). In contrast to the cytoplasmic RLRs, TLR3 engages dsRNA in late endosomes and/or
lysosomes, where it localizes in most cell types (except fibroblasts in which TLR3 can sense
dsRNA on the cell surface). Consistent with this, TLR3 signaling is abrogated by inhibitors
of vacuolar acidification (48), such as bafilomycin A1 and chloroquine.
Among the 10 (12 in mice) known human TLRs, TLR3 is only TLR that does not use the
myeloid differentiation primary response gene 88 (MyD88) adaptor. Instead, it recruits the
TIR-domain containing adaptor inducing IFN-β (TRIF, a.k.a., TICAM1). Upon ligation of
dsRNAs, TLR3 associates with TRIF through homotypic TIR-TIR interactions. TRIF
interacts with TRAF3 and TBK1 through its N-terminal motifs, leading to IRF3 activation.
TRIF can also recruit TRAF6 and RIP1 through N- and C-terminal motifs, respectively,
leading to activation of the IKK complex and NF-κB (82). TLR3 has been shown to mediate
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innate immunity to a number of positive-strand RNA viruses, such as WNV (30), EMCV
(60), poliovirus (123), and HCV (178), in addition to some DNA viruses (84).
In the liver, TLR3 is expressed in stellate cells, Kupffer cells (liver-resident macrophages),
mDCs and billiary endothelial cells (147). TLR3 is also expressed at low levels in normal
human hepatocytes (178). When stimulated with extracellular poly-I:C, primary human
hepatocytes (PHH) strongly induce expression of ISGs, including TLR3 itself and numerous
pro-inflammatory cytokines (73, 98, 178). As is the case in mDCs, TLR3 signaling in
hepatocytes also depends on acidification of the late endosome/lysosome compartment (98).
However, TLR3 is not expressed by Huh-7 hepatoma cells, which are typically used to
propagate HCV in vitro (96). The mechanism responsible for this defect is unclear, but it
may be related to mutation of p53, which regulates TLR3 expression (167). p53 is mutated
in Huh-7 cells and many other hepatoma cell lines.
A role for TLR3 in mediating innate immunity to HCV infection has been demonstrated in
TLR3-reconstituted Huh-7 and Huh-7.5 cells (98, 178). When TLR3 signaling is restored,
the ability of these hepatoma cells to support HCV replication was substantially reduced.
This was associated with activation of IRF3 and induction of ISGs in infected cells.
Remarkably, point mutations in TLR3 that disrupt the dsRNA binding ability of TLR3
ablate the antiviral effect, confirming that TLR3 sensing of HCV dsRNA, and not TLR3
over-expression, is responsible for the inhibition of HCV replication. Interestingly, when
infected at high multiplicity, HCV was able to overwhelm the TLR3-mediated antiviral
effect, consistent with the ability of the major HCV protease, NS3/4A, to inhibit signaling
through this pathway (see Section 5.2.1). In agreement with the fact that TLR3 signaling
activates both IRF3 and NF-κB, reconstitution of TLR3 signaling in Huh-7 cells also
conferred the ability to activate NF-κB and induce pro-inflammatory cytokines, such as
RANTES, MIP-1α, MIP-1β and IP-10 etc. These cytokines are often strongly induced in
HCV-infected liver, possibly due to TLR3 signaling.
The activation of TLR3 by HCV infection requires viral replication that produces dsRNA
duplexes of ≥ ∼80-100bp. However, in contrast to RIG-I, activation of TLR3 is not
dependent on the nucleotide composition or genome position from which HCV dsRNAs
derive (98). The highly structured 3′NTR RNA, which contains a poly-U/UC track that is
highly potent for activating RIG-I (141, 172), was unable to trigger TLR3 signaling unless
annealed with its negative-sense, complementary strand to form dsRNA duplexes. This
suggests that structured regions (such as the stem-loops) in either strand of HCV RNA do
not present the extent of dsRNA structure required for TLR3 signaling or do not form stable
complexes with TLR3 (98). Precisely how HCV dsRNAs generated during viral replication
engage and activate TLR3 in the late endosome/lysosomes is unknown and warrants further
investigation.
3.3. TLR7/8
Both TLR7 and TLR8 recognize single-stranded (ss) RNAs derived from ssRNA viruses
and synthetic imidazoquinoline antiviral compounds such as R848. While not an exclusive
requirement, TLR7 and TLR8 prefers GU-rich and AU-rich RNA sequences, respectively
(84). Similar to TLR3, TLR7 and TLR8 reside in late endosomal compartments and require
endosomal acidification for signaling.
TLR8 is expressed in mDCs and monocytes, and signals mainly to induce NF-κB-dependent
inflammatory cytokines such as TNF-α, IL-6 and IL-10. The TLR8 signaling pathway
depends on recruitment of the MyD88 adaptor, TRAF6, and activation of the classical IKK
complex (83, 104). Little is known about how the TLR8 pathway functions in HCV
infection.
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TLR7 is expressed mainly, if not exclusively, in pDCs. These cells sense viral RNAs upon
viral entry/uptake or delivery of the RNA to lysosomes from the cytoplasm through
autophagy (as shown with viruses replicating in pDCs such as VSV). Activated pDCs
initiate signaling cascades leading to rapid production of type I IFNs (83), at levels
100-1000 times higher than that produced by any other blood cell type (104). This process
involves the recruitment of MyD88, TRAF6, TRAF3, and the kinases IRAK1 and IKKα,
which phosphorylate and activate IRF7. Unlike other immune and non-immune cell types,
pDCs constitutively express IRF-7, explaining why they have the unique capacity to rapidly
produce extraordinarily high levels of type I IFNs upon sensing viral RNAs through the
TLR7 pathway, without the need for IFN-mediated autocrine/paracrine signaling (83, 104).
TLR7 agonists are effective in reducing viremia in hepatitis C patients, and this correlates
with the induction of endogenous IFN production (68). This supports the relevance of TLR7
signaling to host defenses against HCV. Because pDCs are “professional” IFN producing
cells that utilize the TLR7 pathway (104) and infiltrate HCV-infected liver (91), the role of
TLR7 in sensing HCV infection has been studied mainly in pDCs. When transfected with
HCV RNA, pDCs produce significant amounts of IFN-α (162, 186). More physiologically
relevant, freshly isolated pDCs placed in co-culture with Huh-7.5 cells infected with JFH-1
virus or containing replicating RNA replicons (i.e., the stimulator cells) demonstrate robust
production of type I IFNs. This response is dependent on HCV RNA replication in the
stimulator cells, close proximity of the stimulator cells to pDCs, and signaling through
TLR7. The pDCs are not actively infected by HCV, and the mechanism underlying the
transfer of HCV RNA from stimulator cells to pDCs remains to be elucidated (162). A
puzzling fact is that HepG2, HEK293, HeLa or mouse hepatoma cells harboring HCV
replicons failed to activate co-cultured pDCs to produce IFN when similarly stimulated.
Whether the TLR7 pathway functions in human hepatocytes to induce antiviral responses to
HCV infection is unclear. TLR7 mRNA is expressed at low level in hepatocytes (92). The
stimulation of Huh-7 replicon-bearing cells by a potent TLR7 ligand, SM360320,
moderately reduced HCV replication without inducing type I IFNs (92). However, when
PHH cultures were treated with R848, a well-characterized TLR7/8 ligand, there was no IFN
or ISG induction (178).
3.4. PKR
The dsRNA-activated Protein kinase R (PKR, a.k.a., EIF2AK2) is a serine/threonine kinase
that regulates protein synthesis, cell proliferation, apoptosis, and signal transduction. PKR is
comprised of tandem N-terminal dsRNA binding motifs (DRBM) and a C-terminal catalytic
domain. dsRNAs longer than 30-bp or short imperfect stem-loop RNAs bearing 5′-
triphosphates can bind to the DRBM of PKR, triggering PKR dimerization and auto-
phosphorylation. This converts PKR into an active kinase capable of phosphorylating
protein substrates such as the translation initiation factor eIF2α, which results in shut-off of
protein synthesis (61, 129). PKR also interacts with various TRAFs and activates NF-κB,
although the mechanism of this remains poorly characterized (129). PKR was the first PRR
shown to recognize dsRNA. However, the original proposal that PKR serves as a PRR
mediating IFN induction to viruses has been largely dismissed since the discovery of the
RLRs. Nonetheless, it is puzzling that PKR is essential for IFN production to certain but not
all viral infections (7, 21, 55). This may be partially explained by a recent study
demonstrating that PKR contributes to responses against RNA viruses that are primarily
sensed by MDA5 by regulating the stability of mRNAs for IFN-β and IFN-α. In PKR
deficient cells infected with EMCV, TMEV and SFV, the induction of type I IFN mRNAs
was normal, but no IFN-β/α proteins were made because the IFN mRNAs lacked poly(A)
tails (146). PKR is phosphorylated in Huh-7 cells upon transfection of JFH-1 genomic RNA,
but not a replication-defective counterpart (76), and upon infection with JFH-1 virus (5, 53).
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This suggests that dsRNAs generated during HCV replication activate PKR. In HCV-
infected Huh-7 cells, PKR was found to bind to HCV RNA (although it was unclear whether
PKR acted as a PRR or an adaptor) early after infection, and to recruit MAVS and TRAF3
prior to RIG-I, resulting in activation of IRF3 and the induction of a small subset of ISGs
(5). Paradoxically, this early activation of PKR-dependent host responses seemed to benefit
the virus rather than the host, as it delayed activation of RIG-I signaling (see details in
section 5.2.1). Overall, the role played by PKR in innate antiviral response to HCV is
uncertain. Depending on experimental conditions, PKR has been found to act with either
antiviral or proviral effect (see Section 4.4).
3.5. TLR2
TLR2 is expressed on plasma membrane of monocytes and some other cell types. It acts in
concert with TLR1 or TLR6 in recognizing bacterial and fungal cell wall components as
well as certain viral proteins. Upon engagement, TLR2 recruits MyD88 through a bridging
adaptor, MyD88 adaptor-like (MAL, a.k.a., TIRAP), and relays signals to IRAK kinases and
TRAF6, leading to activation of the IKK complex and NF-κB and production of
inflammatory cytokines (83). TLR2 was shown to mediate a response to recombinant HCV
core and NS3 proteins by human monocytes, resulting in activation of NF-κB, MAP kinase
and production of IL-10 and TNFα. This innate recognition mechanism, however,
contributes to inflammatory responses and impairs DC differentiation rather than facilitates
anti-HCV immunity (35, 36). Of note, the TLR2 pathway has been shown to be functional in
inducing TNFα expression following stimulation by synthetic TLR2 ligands in various
hepatocyte cell lines (132). Hepatic expression of TLR2 and TNF-α correlates with hepatic
inflammatory activity in hepatitis C patients, as does TLR2 expression in peripheral blood
monocytes (9, 138).
4. ISGs that demonstrate antiviral activity against HCV
More than 300 ISGs are transcriptionally regulated by IFNs through the Jak-Stat signaling
pathway, but only a small fraction of them have been experimentally examined for antiviral
actions (16). Among these, some have demonstrated antiviral activity against HCV in vitro
and are discussed below. In addition to these ISG proteins, a small number of microRNAs
(miRNAs) can be also induced by IFN and may be capable of targeting the HCV genome
and inhibiting HCV replication (127). Overall, how the effector functions of the innate
immune system control HCV infection represents a robust area of current investigation.
While there are a number of examples described below in which results from different
studies have been contradictory or inconsistent, this is likely to be due to differences in the
specific cells studied or perhaps levels of expression of HCV proteins that counteract these
mechanisms (see Section 5). There is also a high degree of redundancy in innate immune
control mechanisms targeting HCV.
4.1. The OAS-RNase L system
Transcriptionally upregulated by IFNs, the 2′,5′-oligoadenylate synthetases (OASs)
catalyze the production of 3-6-base-long, 2′-to-5′ linked oligoadenylates (2-5A) from ATP.
During viral infections, viral dsRNA activates one of the 3 functional human OASs
(OAS1-3) to synthesize 2-5A, which in turn, binds to and activates the latent RNase L
enzyme. Upon dimerization, RNase L becomes a potent endoribonuclease that cleaves
single-stranded regions of RNA substrates at UA and UU dinucleotides. In addition to
targeting viral RNAs, RNase L also processes and degrades cellular mRNAs and rRNAs,
halting protein synthesis and inducing apoptosis of infected cells (153). Evidence suggesting
the OAS-RNAse L system acts as an IFN-induced antiviral effector against HCV came from
a study conducted by Han and Barton (59), who demonstrated that HCV RNA was detected
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and destroyed by RNase L in cytoplasmic extracts of HeLa cells. Interestingly, HCV RNAs
from the more IFN-resistant genotypes, 1a and 1b, were found to have fewer UA and UU
dinucleotides than those from relatively IFN-sensitive genotypes (genotype 2 and 3),
offering a potential explanation for the different sensitivity of HCV genotypes to IFN
therapy seen in clinics.
4.2. ISG20
The IFN-stimulated gene 20 kDa protein (ISG20) has recently emerged as a second IFN-
regulated RNase that suppresses RNA virus replication (33). Classified within the DEDDh
exonuclease family, ISG20 acts as a 3′-5′ exonuclease that has a preference for ssRNA over
ssDNA (121). Ectopically expressed ISG20 strongly inhibited replication of subgenomic,
genotype 1b HCV RNA replicons in HEK293 cells (71) and propagation of cell culture-
derived genotype 2a JFH-1 virus in hepatoma cells (188). Although the underlying
mechanism remains poorly understood, ISG20 acts via its exonuclease activity to exert an
anti-HCV effect (71, 188). A catalytically inactive mutant of ISG20 exerted a dominant
negative (DN) effect on the antiviral activity of IFN-α against subgenomic JFH-1 replicons,
suggesting ISG20 is a significant contributor to the overall antiviral effects of IFN (188).
4.3. RSAD2
Accumulating evidence suggests the radical S-adenosyl methionine (SAM) domain
containing 2 (RSAD2, a.k.a. viperin or cig5) is a potent antiviral factor against a broad range
of RNA viruses from distinct families. Initially identified as a cytomegalovirus-induced
protein, RSAD2 is now known to be strongly induced by dsRNA and lipopolysaccharides,
as well as type I IFN and, to a lesser extent, by IFN-γ (116). Highly conserved from
vertebrates to mammals, RSAD2 has an N-terminal amphipathic helix domain that directs
RSAD2 to the ER and also lipid droplets (65), a central region containing 4 conserved SAM
motifs whose function is ill-defined, and a C-terminal portion important for RSAD2
dimerization (116). When overexpressed, RSAD2 potently inhibited HCV replication in
HCV-N replicon-bearing Huh-7 (63) and HEK293 cells (71), and in JFH-1-infected Huh-7
cells (62, 179). The mechanism by which RSAD2 inhibits HCV replication is poorly
understood. RSAD2 associates with the vesicle-associated membrane protein-associated
protein A (VAP-A) (62, 179), and disrupts the interaction of the latter with NS5A (179),
which is required for assembly of the HCV replication complex on lipid membranes (52).
However, Jiang et al. (71) showed that the SAM domain was important for the anti-HCV
activity of RSAD2 in HEK293 cells, while Wang et al. (179) and Helbig et al. (62) found
the C-terminal region and not the SAM domain to be important in HCV-infected Huh-7
cells. Helbig et al. (62) also found the N-terminal amphipathic helix to be indispensable. In
addition, Helbig et al. (62) found that RSAD2 interacted with both NS5A and VAP-A by
FRET analysis, while Wang et al. (179) reported that RASD2 associated with VAP-A but
not NS5A by co-immunoprecipitation. These inconsistencies could be attributed to
differences in experimental approaches and/or cell types.
4.4. PKR
In addition to its possible dsRNA sensor functions discussed above, PKR may act as an
effector of the innate immune response. However, studies examining the impact of PKR on
the HCV life cycle have provided mixed results. Direct evidence for an antiviral role in
HCV replication came from a study by Chang et al. (23) who demonstrated that subgenomic
JFH-1 strain RNAs replicated more efficiently in PKR−/− knockout MEFs than in wild-type
(WT) MEFs. Subsequently, overexpression of PKR was shown to inhibit HCV 1b replicons
in HEK293 (71) and Huh-7 cells (70) and to suppress HCV antigen expression in JFH-1-
infected Huh-7 cells (76). In Huh-7 cells with stable knockdown of PKR, transfection of
genomic JFH-1 RNA yielded more infectious progeny viruses than in control Huh-7 cells
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(22, 76). PKR depletion also up-regulated HCV RNA abundance in JFH-1 replicon-bearing
WT MEFs (23). Precisely how PKR exerts its antiviral function is unclear, but the kinase
activity of PKR appears to be important (71, 76). It is likely to involve phosphorylation of
eIF2α, which results in a global suppression of protein synthesis. HCV replication was
inhibited by over-expression of a phospho-mimetic eIF2α mutant (76), while expression of
PKR was associated with modest retardation in cell growth (71). However, translation
initiation mediated by the HCV IRES is relatively insensitive to eIF2α phosphorylation (6,
152). Thus, it is possible that PKR inhibits HCV replication in part by limiting the
expression of proviral cellular factors, the translation of which are eIF2α-dependent. In
contrast, others have reported that transient knockdown of PKR has no effect on HCV RNA
replication or progeny virus production in Huh-7 cells (53), or is actually detrimental to
replication and virus production in Huh-7.5 cells (135). Thus, while PKR may help to
control of HCV infection, its overall role in HCV pathogenesis is uncertain. As discussed
below in Section 5.2.3, PKR activation may actually be counterproductive from the host
perspective, as it may limit the synthesis of ISG effector proteins (53).
4.5. ADAR1
Adenosine deaminase acting on RNA (ADAR) 1 catalyzes the adenosine (A) to inosine (I)
editing of viral and cellular RNAs possessing double-stranded structures. Because I is
recognized as G by ribosomes and RNA polymerases, RNA editing by ADAR1 results in
nucleotide substitutions that could alter mRNA translation, RNA structure and/or stability,
and RNA-protein interactions (54). All of these can ultimately impact viral replication. IFN-
α promotes ADAR1 editing of HCV RNAs in genotype 1b replicon-bearing Huh-7 cells,
while HCV RNA replication is enhanced following siRNA knockdown of ADAR1 or
inhibition of ADAR1 function by adenovirus associated VA RNAI (168).
4.6. IRF1 and IRF7
Kanazawa et al. (75) found that IRF1 basal expression was lower in Huh-7 cells selected to
support the replication of an HCV-N replicon than in parental Huh-7 cells. Upon
reconstitution of IRF1 expression, the highly permissive phenotype of IFN-cured replicon
cells was reversed. Consistent with this, over-expression of IRF1 strongly inhibited HCV
replication in Huh-7 replicon cells as well as in JFH-1-infected Huh-7.5.1 cells (69, 70). A
role for IRF7 in limiting HCV replication has also been suggested. Aly et al. (4) reported
that inhibition of IRF7 function by over-expression of DN-IRF7 or by siRNA-mediated
depletion of IRF7 enhanced the permissiveness of HPV18/E6E7-immortalized human
hepatocytes for infection by JFH-1 virus or by serum-derived HCV isolates (genotype 2b
and 4a). The antiviral effect of IRF1 and IRF7 against HCV infection was confirmed in a
recent ISG screening study (145). Given the known role of IRF1 and IRF7 as transcription
factors controlling IFN and ISG expression (163), it is not a complete surprise that both
would have antiviral activity against HCV. Although direct effects on HCV cannot be ruled
out, these IRFs likely execute their antiviral function through inducing IFNs and/or other
antiviral ISGs. This notion is supported by the fact that IRF1 and IRF7 were found to be
more potent in inhibiting HCV replication than other modestly inhibitory ISGs (69, 145).
4.7. IFIT1
The IFN-induced protein with tetratricopeptide repeats 1 (IFIT1, a.k.a. p56, ISG56) binds to
the p48 subunit of the eIF3 complex and inhibits its function in initiation of protein synthesis
(57). Wang et al. (177) showed that IFIT1 associated with eIF3 in the active HCV RNA
translation initiation complex, thereby suppressing HCV IRES-mediated viral RNA
translation. Raychoudhuri et al. (136) found overexpression of IFIT1 inhibited the
replication of con1 and JFH-1 subgenomic HCV RNA replicons in Huh-7 cells, and reduced
HCV RNA levels in Huh-7 and immortalized human hepatocytes (IHHs) infected with
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JFH-1 virus. However, others reported that ectopic expression of IFIT1 did not influence
colony formation efficiency in HEK293 cells transfected with a selectable, subgenomic
HCV-N replicon that has been adapted in HeLa cells (71). Since the HCV IRES sequence is
highly conserved among different genotypes, it is possible that this discrepancy reflects a
cell-type specific effect of IFIT1 on IRES function.
4.8. IFITM1
Raychoudhuri et al. (136) reported that transient expression of the IFN induced
transmembrane protein 1 (IFITM1, a.k.a., 9-27) suppressed HCV RNA accumulation in
Huh-7 cells bearing subgenomic con1 and JFH-1 replicons. IFITM1 over-expression also
reduced HCV RNA levels in Huh-7 and IHH cells infected with JFH-1 virus, while
knockdown of IFITM1 had the opposite effect . In contrast, Jiang et al. (71) did not observe
an effect of IFITM1 on replication of HCV-N replicon in HEK293 cells.
4.9. GBP1
Classified within the dynamin superfamily of large GTPases, the guanylate binding protein 1
(GBP1) is a type I and II IFN-inducible GTPase that exhibits antiviral and antibacterial
activities (174). When ectopically expressed, GBP1 moderately inhibited HCV replication in
Huh-7 cells bearing HCV-N or JFH-1 replicons, and restricted JFH-1 virus replication in
Huh-7.5.1 cells. On the other hand, knockdown of GBP1 enhanced HCV replication. The
antiviral mechanism of GBP1 is unknown. While the GTPase activity was shown to be
essential, GBP1 did not inhibit HCV IRES activity, nor did it activate ISG expression or
affect signaling pathways such as NF-κB and AP-1 (69, 70). In contrast to these findings,
however, forced expression of GBP1 had no apparent impact on replication of an HCV-N
replicon in HEK293 cells (71).
4.10. IFITM3
The antiviral effect of the IFN induced transmembrane protein 3 (IFITM3, a.k.a., 1-8U)
against HCV was first reported by Zhu et al. (190) while studying the antiviral effector
mechanism of a proinflammatory cytokine, IL1, against the replication of subgenomic HCV-
N RNA replicon in Huh-7 cells. These authors showed that IFITM3 was induced by IL1 as
well as by IFN-α and that over-expression of IFITM3 reduced HCV RNA abundance in
replicon-bearing cells. How IFITM3 exerts its anti-HCV effect remains elusive, but it was
recently reported that IFITM3 suppresses both cellular and HCV IRES-dependent
translation (182). It should be noted, however, IFITM3 was reported not to inhibit HCV-N
replicon in HEK293 cells (71).
4.11. Other ISGs
Other less well-characterized ISGs implicated in restricting HCV replication include the IFN
alpha-inducible protein 6 (IFI6, a.k.a, 6-16) and IFN alpha-inducible protein 27 (IFI27,
a.k.a, ISG12). Itsui et al. (69, 70) have reported that both proteins, when over-expressed,
moderately reduce HCV replication in HCV-N replicon-bearing Huh-7 cells and JFH-1-
infected Huh-7.5.1 cells. However, Jiang et al. (71) documented a lack of antiviral effect of
IFI27 on HCV-N replicon in HEK293 cells.
5. Evasion and counteraction of innate immunity by HCV
A growing body of evidence suggests that HCV has developed multilayered strategies to not
only evade but also actively counteract host innate defenses. These are likely to contribute to
the extraordinary ability of HCV to establish persistent infection.
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In the blood of hepatitis C patients, HCV virions are associated with host lipids and proteins
such as the lipoproteins and circulate as heterogeneous particles, which physiochemically
resemble very low density lipoprotein particles (160). This may disguise HCV from
recognition by the host immune system including the innate immune cells.
In infected hepatocytes, HCV replicates its RNAs within rearranged cytoplasmic membrane
vesicles, usually derived from the ER (41, 56). This highly compartmentalized
microenvironment is typical of positive-strand RNA viruses, and may shield HCV
replication complexes from attacks by cellular nucleases and proteinases as well as from
sensing by the cytoplasmic RLRs. In addition, various groups have reported that HCV
induces autophagy, an evolutionally conserved, ancient process by which cells recycle
cytoplasmic constituents through the lysosomal pathway under stress conditions, to facilitate
its own life cycle (2, 37, 154, 164). Importantly, the induction of autophagy may help HCV
evade RIG-I-mediated innate antiviral immunity, as knockdown of autophagy components
enhanced induction of IFN-β and ISGs in Huh-7 cells following stimulation by HCV 3′UTR
RNA, a PAMP sensed by RIG-I (85). Certain autophagy-related proteins, such as Atg5-
Atg12 conjugates, can associate with the CARDs of RIG-I and MAVS and interfere with
RIG-I signaling (74). Autophagosome formation may also sequester viral PAMPs from
recognition by cytoplasmic RLRs. Supporting the latter notion, HCV RNAs have been
found to be concealed in autophagosome-like structures - double membrane vesicles
decorated with LC3-II, a specific marker of autophagic membranes, in Huh-7.5 cells
replicating subgenomic JFH-1 replicons (43).
HCV is known to hijack miR-122, a liver specific miRNA, to physically stabilize and
facilitate replication of its genome (72, 151). This involves binding of miR-122 to the HCV
5′NTR at two sites near the 5′ end of the genome in association with Ago2. This appears to
protect HCV RNAs from cellular 5′ exonucleases (151), but it could also limit recognition
of the 5′ triphosphate of the genome by RIG-I. However, this mechanism of evasion, if
proven, would only impair cellular sensing of positive-strand HCV RNAs, as any 5′
triphosphate present in the negative-strand RNA would also be recognized by RIG-I.
Because the NS5B RNA-dependent RNA polymerase lacks proofreading activity, HCV
replication is error-prone. Thus, under the continuous selection pressure imposed by the host
immune system, HCV exists as a heterogeneous population comprising genetically related
viral variants known as “quasispecies” (112). Not only does this provide a mechanism by
which HCV accumulates mutations allowing escape from cytotoxic T-cells and neutralizing
antibodies, but it also may aid HCV RNA to evade OAS-RNase L-mediated antiviral
responses. Notably, in hepatitis C patients treated with IFN, HCV RNAs were found to
accumulate silent mutations over time preferentially at UA and UU dinucleotides, the
cleavage sites for RNase L (59).
5.2. Counteraction
5.2.1. Inhibition of the induction of IFNs—HCV has been reported to activate a PKR-
MAVS-TRAF3-IRF3 pathway early after infection in Huh-7.25.CD81 cells and prior to its
recognition by RIG-I, leading to upregulation of a small subset of ISGs (5). One of the most
highly induced genes was ISG15, which negatively affected RIG-I ubiquitylation by
TRIM25, a prerequisite for interaction of RIG-I and its adaptor MAVS (49). Silencing of
ISG15 expression restored RIG-I ubiquitylation and early IFN-β induction, and correlated
with a reduction in HCV replication (5). This study thus suggests that HCV may subvert a
PKR-mediated immediate host response to inhibit innate immune signaling at the PRR level.
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HCV is known to interfere with activation of IFN response via both MAVS- and TRIF-
dependent pathways (20, 73, 97, 125). The NS3/4A protease of HCV has been shown to
target both MAVS and TRIF for proteolysis. The evidence for HCV hydrolysis of MAVS is
especially strong. NS3/4A cleaves MAVS at Cys508 immediately before the C-terminal
transmembrane domain, dislodging MAVS from the mitochondrial outer membrane and/or
mitochondrial associated membrane, the platform for RLR signaling (67, 99, 108, 119).
Remarkably, MAVS cleavage was also observed in the liver of hepatitis C patients, although
the reported frequency varied, and how MAVS cleavage relates to the reduced activation of
endogenous IFN remains debated (8, 108, 157). The cleavage of MAVS likely contributes to
HCV pathogenesis, but is unlikely to be the proximate cause of viral persistence (93). Two
other hepatotropic positive-strand RNA viruses, GB virus B and hepatitis A virus (a
picornavirus), also encode a protease or protease precursor that cleaves MAVS (26, 181).
Although disruption of MAVS signaling is as efficient as with HCV, both of these viruses
typically cause self-limiting infections in vivo.
TRIF is cleaved by purified NS3/4A protease in cell-free reactions at Cys372, a site bearing
remarkable sequence homology to the NS4B/5A cleavage site in HCV polyprotein,
separating the N-terminal TBK1 and TRAF binding domains from the C-terminal TIR
domain (44, 97). TRIF protein abundance was substantially reduced in HeLa cells bearing
HCV replicons (97) and in Huh-7.5 cells infected with JFH-1 virus (178), and this could be
partially reversed by short term treatment of a specific NS3/4A inhibitor. Consistent with
this, HCV infection substantially blunted the induction of ISGs in response to extracellular
poly-I:C (178). However, the reduction of TRIF abundance by NS3/4A has not been seen in
some other experimental settings (31, 73). It is possible that this reflects differences in TRIF
or NS3/4A localization within the cell, as well as technical difficulties in detecting this
relatively low abundance protein.
HCV NS5A has been reported to interfere with MyD88-dependent TLR signaling pathways
when stably expressed in the Raw264.7 mouse macrophage cell line (1). NS5A from
different HCV genotypes bound to MyD88 in co-transfected HEK-293T cells, and this
interaction disrupted the recruitment of IRAK1 to MyD88, ultimately inhibiting cytokine
production following stimulation by various TLR ligands. Interestingly, this interaction was
mapped to a previously recognized “interferon sensitivity-determining region” (ISDR)
region in NS5A (42), which associated with the death domain of MyD88. It should be noted,
however, this mechanism of immune evasion is operative only if active infection and
replication of HCV takes place in DCs and monocytes/macrophages, which remains a
subject of debate.
At the kinase level, it has been reported that HCV NS3 interacts directly with TBK1 to
inhibit the activation of IFN-β-promoter by TRIF and TBK1 (125). The C-terminal helicase
domain of NS3 competed with IRF3 for interacting with TBK1, thereby interfering with
IRF3 activation by TBK1. Such an effect would be likely to impact both RIG-I and TLR3
signaling. In addition, Tasaka et al. (166) reported that HCV NS4B inhibited the activation
of IFN response by overexpression of RIG-I or MAVS through an undefined mechanism.
However, others have found that NS4B does not impair RIG-I signaling (45, 81).
Despite all of the evidence that HCV proteins are able to disrupt the IFN induction pathways
in vitro, there is strong evidence that ISG expression is induced in HCV-infected liver in
vivo (11, 142, 158). However, this may be explained by the finding that HCV only infects a
small proportion of hepatocytes in the liver (100, 157). IFNs may still be induced in newly
infected hepatocytes at an early stage of infection prior to abundant HCV proteins being
made, or in uninfected pDCs infiltrating the liver that sense HCV-infected hepatocytes.
Nonparenchymal liver cells may also sample viral nucleic acids released from infected cells
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undergoing necrotic death to produce IFNs. Collectively, the IFNs produced could act in a
paracrine/autocrine fashion to upregulate ISG expression in the liver. Significantly, high-
level endogenous expression of ISG transcripts within the liver correlates with both poor
response to treatment with Peg-IFN/RBV and the unfavorable IL28B haplotype (66, 142).
However, the mechanism underlying this association is unknown.
5.2.2. Inhibition of IFN signaling downstream of the IFN receptors—A large body
of data suggests that HCV also impairs IFN signaling downstream of the IFN receptors via
numerous mechanisms (Fig. 3). In transfected cell lines, both core and NS5A appear to
interact with Stat1 and impair IFN-induced Stat1 phosphorylation, thereby inhibiting
downstream ISG transcription (89, 101). Core was also found to interfere with Stat1 nuclear
translocation (14, 117) or binding of ISGF3 to the ISRE in ISG promoters (32). Over-
expression of core was associated with the induction of suppressor of cytokine signaling-3
(SOCS3) (14), which targets Janus kinases (Jaks) to inhibit Stat1 phosphorylation.
IFN-α-induced Jak-Stat signaling was impaired in transgenic mice expressing the HCV
polyprotein (12) and in living cells from liver biopsies from chronic hepatitis C patients
(39). IFN-induced Stat1 phosphorylation was intact, but the binding of Stat1 to ISG
promoters was significantly compromised. Protein phosphatase 2A (PP2A) was up-
regulated, presumably as a result of ER stress, and this was associated with hypomethylation
of Stat1 on Arg 31, probably due to the inhibition of PP2A on protein arginine
methyltransferase 1 (PRMT1). The hypomethylation of Stat1 promotes its association with
protein inhibitor of activated STAT1 (PIAS1), a negative regulator of the transcriptional
activity of Stat1 (28, 38).
Expression of NS5A has been shown to induce IL8 mRNA and protein, which, in turn,
attenuates IFN's antiviral action in HeLa cells (130). Interestingly, not only were serum IL8
levels higher in hepatitis C patients than in healthy control subjects, but IL8 levels were
significantly elevated in patients who did not respond to IFN therapy compared with those
who did respond to therapy (131).
Despite the reported inhibitory effects of HCV proteins on IFN signaling, genome-length
HCV RNA replicons are sensitive to IFN treatment. Replicon-bearing cells can be cured by
either type I or II IFNs. However, HCV-infected cells have been shown to be significantly
more resistant to IFN than replicon cells (53). Nonetheless, there are data from HCV-
infected hepatoma cells that do not support the notion that HCV interferes with Jak-Stat
signaling. In Huh-7 cells infected with JFH-1 virus, neither transcription from the ISRE
promoter nor induction of ISG mRNAs was impaired following stimulation with IFN (27,
53). Thus, more studies in the context of HCV infection in vivo will be required to reconcile
this inconsistency.
There are yet other views on why some hepatitis C patients fail to respond to PegIFN/RBV
therapy. In chimpanzees chronically infected HCV, the intrahepatic ISG expression was
already maximally induced. As a result, there was no further up-regulation of ISGs when
exogenous IFN was administered (90). Consistent with this, it was found that in chronic
hepatitis C patients undergoing PegIFN/RBV therapy, a poor response was associated with
higher expression levels of ISGs prior to therapy (66, 142). Others reported that pre-
activation of the ISGylation/de-ISGylation pathway involving the ubiquitin-like modifier,
ISG15 and its deconjugating enzyme, ubiquitin-like specific protease 18 (USP18, a.k.a.,
Ubp43) in hepatocytes, not only promoted HCV replication but correlated with poor
response to IFN therapy in hepatitis C patients (25). An ISG that is significantly elevated in
non-responders compared with responders, USP18 is known to dampen IFN signaling to the
Jak-Stat pathway via de-ISGylation as well as by disrupting the association between
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IFNAR2 and JAK1 in a protease-independent fashion (109). In cell culture, siRNA-
mediated depletion of USP18 enhanced ISG induction as well as the antiviral effect of IFN-
α against HCV replication (133).
5.2.3. Inhibition/subversion of the function of antiviral effector ISGs—Both
NS5A and E2 of HCV have been reported to bind to PKR and inhibit its effector function.
Gale et al. (50, 51) reported that the NS5A of HCV genotype 1b directly bound to the PKR
catalytic domain and inhibited PKR dimerization and phosphorylation of its substrate,
eIF2α. The ISDR along with a stretch of 26 amino acids carboxyl to it were responsible for
both PKR association and repression. In the case of E2, Taylor and colleagues (169) found
that the E2 proteins from genotypes 1a and 1b contain a 12-amino acid sequence
homologous to the PKR autophosphorylation site and the phosphorylation site of eIF2α.
They demonstrated that E2 bound to PKR mainly through this site and that this inhibited
PKR's kinase activity and effect on protein synthesis. A cytosolic, unglycosylated form of
E2 was found to mediate the PKR interaction (126). However, the reported effects of NS5A
and E2 on PKR have varied depending on HCV isolates and experimental systems used, and
have not been consistently demonstrated by different research groups. Attempts at clinical
correlations have not reached a consensus (13), and these findings have yet to be validated
using the infectious HCV culture systems.
Two recent studies revealed that HCV hijacks PKR function to inhibit host protein
synthesis, thereby antagonizing RIG-I-mediated IFN production (6) or IFN-induced antiviral
action (53). Both studies demonstrated HCV infection of Huh-7 cells activated PKR auto-
phosphorylation and eIF2α phosphorylation, resulting in inhibition of host protein synthesis.
These effects were more pronounced in cells also treated with IFN (53). However, HCV
replication was not affected because HCV IRES-mediated translation was relatively resistant
to eIF2α phosphorylation. Surprisingly, PKR activation suppressed HCV-induced IFN
production (6) and blocked ISG protein expression from mRNA (53). Inhibition of PKR
function in HCV-infected cells restored IFN induction (6) and IFN-induced ISG protein
expression, and enhanced the antiviral effects of IFN (53). Of note, these results are in
contrast to earlier studies showing PKR to be an anti-HCV factor in various cellular systems
with replicons or transfection of JFH-1 genomic RNA (22, 23, 70, 71, 76).
There is also evidence that genotype 1b HCV NS5A physically interacts with OAS1 via its
N-terminal one-third when both proteins are ectopically co-expressed in HeLa cells (161).
The NS5A fragment capable of binding to OAS1 was as effective as the full-length NS5A in
antagonizing IFN action against EMCV. Whether NS5A expressed from replicating HCV
RNA could also associate with endogenous OAS1 was not studied, but a genotype 1b
replicon with a point mutation in NS5A that disrupted the NS5A-OAS1 interaction had
reduced fitness when transfected into Huh-7 cells.
Finally, HCV NS5B has been reported to bind to the N-terminal GTPase domain of GBP1
via its fingers domain when ectopically expressed in HEK-293T cells. This interaction
suppressed the GTPase activity of GBP1 and was able to relieve the moderate inhibitory
effect of GBP1 on HCV replication in genotype 1b replicon-bearing Huh-7 cells (69).
6.0 Perspective and Concluding Remarks
Although many lines of evidence suggest that HCV infection disrupts IFN responses at
multiple levels as described above, it is clear that ISGs are often prominently expressed in
the liver in both acute and chronic infections (10, 142, 158). High-level expression of ISGs
within the liver prior to treatment is associated with high serum levels of IP10 and is
strongly predictive of a poor therapeutic outcome (142). In contrast, patients who experience
rapid virologic responses to PegIFN/RBV therapy have low pre-therapy expression of ISGs
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within the liver, but demonstrate impressive up-regulation of these genes when treated. This
is a mystery that is yet to be resolved. The pattern of ISG expression within PBMCs differs
substantially from that in the liver, and does not correlate with treatment outcome. The
underlying reason for the liver-specific nature of pre-treatment ISG expression is unknown,
but is consistent with it being driven primarily by IFN-λ,or alternatively by IFN-α/β
produced locally within the liver. Exactly why this pre-treatment response occurs in some
patients (IFN non-responders) and not in others (rapid responders) is not known, nor is it
understood why patients that have high endogenous antiviral responses do not spontaneously
clear their infection. There are clues that can be deduced from the work described in the
preceding sections, most of which was done using in vitro systems, but just as many gaps in
our knowledge. Underlying all of this is the fact that we simply do not understand the
mechanism responsible for the profound association of IL28B genotype with both infection
outcome and response to Peg-IFN/RBV therapy.
Thus, although much has been learned about the functions of various HCV proteins and the
mechanism of HCV replication since identification of the virus more than two decades ago,
we have only a limited understanding of how the host immune system, and in particular the
innate immune system, interacts with HCV. To no small part, this can be attributed to the
lack of a convenient, immunocompetent small animal model and efficient cell culture
systems possessing uncompromised innate immune systems. Hopefully, this area will
advance with the development of mouse models that fully recapitulate the HCV life cycle
and the improvement of HCV culture systems employing primary cultures of normal human
hepatocytes. New knowledge of the interplay between HCV and innate immune responses
would undoubtedly help our understanding of HCV pathogenesis and the development of
effective immunotherapy for chronic hepatitis C.
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Figure 1. Organization of the HCV genome and the proteins HCV encodes
The ∼10-kb positive-sense, single-stranded RNA genome encodes a large polyprotein that is
processed into 10 individual proteins by a combination of viral and cellular proteases.
Flanking the HCV polyprotein are the highly structured, 5′- and 3′-nontranslated regions
(NTRs) important for viral RNA replication and/or protein translation. A frameshift (F,
a.k.a., ARF) protein may be expressed from the core-coding region as a result of translation
from an alternative reading frame. The junctions between the structural proteins, C, E1 and
E2 (shaded in light blue) and those between E2 and p7, p7 and NS2 are cleaved by cellular
signal peptidase (filled triangles). An additional processing proximal to the C-terminus of
core is mediated by cellular signal peptide peptidase (empty triangle). NS2, along with the
N-terminal portion of NS3, constitute the NS2-3 autoprotease that cleaves the NS2-3
junction. The downstream NS proteins are processed by the NS3 serine protease with the aid
of the cofactor NS4A. Among the NS proteins (shaded in light yellow), only NS3 to NS5B
are required for HCV RNA replication. In addition to its role in viral replication, NS5A
contains an IFN sensitivity-determining region (ISDR, spanning codons 2209 to 2248),
which has been associated with efficacy of IFN therapy in genotype 1b HCV-infected
Japanese patients.
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Figure 2. Innate intracellular signaling pathways that sense RNA virus infections and lead to
expression of type I and III IFNs, cytokines and chemokines
Viral dsRNAs and 5′-triphosphate-bearing, poly-U rich viral RNAs are recognized by the
RLRs (RIG-I, MDA5 and LGP2) that are constitutively expressed in the cytoplasm and that
initiate MAVS-dependent signaling leading to activation of IRF3/7 and NF-κB, and
ultimately, synthesis of type I and III IFNs and inflammatory cytokines/chemokines. Viral
dsRNAs can also be sensed by TLR3 in late endosomes and trigger a TRIF-dependent
pathway activating innate immune responses. Both the RIG-I and TLR3 pathways are
capable of sensing HCV infection in hepatocytes. Viral ssRNAs can be sensed by TLR7 or
TLR8 in endosomes and activate MyD88-dependent innate immune responses. TLR7
operates exclusively in pDCs and mainly results in IRF7 activation and subsequent
induction of IFN-α and IFN-λs, while TLR8 operates in mDCs and mainly leads to
expression of NF-κB-dependent cytokines. pDCs use the TLR7 pathway to sense co-
cultured HCV-infected hepatocytes, resulting in IFN-α production.
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Figure 3. Induction of ISGs by type I and III IFNs through the JAK-STAT signaling pathway
and its inhibition by HCV
Type I and III IFNs bind to distinct, heterodimeric cell surface receptors, but then activate a
similar intracellular signaling pathway involving recruitment and activation of the Janus
kinases, JAK1 and TYK2, phosphorylation of STAT1 and STAT2, and the formation of the
heterotrimeric transcription factor complex, IFN-stimulated gene factor-3 (ISGF3)
comprising phosphorylated STAT1 and STAT2 and IRF9. ISGF3 migrates into the nucleus
and induces the transcription of hundreds of ISGs by binding to the IFN-stimulated response
element (ISRE) in ISG promoters. HCV core and NS5A associate with STAT1, suppressing
its phosphorylation and/or nuclear translocation. Core can also induce SOCS3 expression,
which negatively regulates JAK. HCV-induced endoplasmic reticulum stress up-regulates
expression of protein phosphatase 2A (PP2A), which inhibits the transcriptional activity of
STAT1 by suppressing protein arginine methyltransferase 1 (PRMT1), thereby promoting
STAT1 hypomethylation and STAT1 association with the protein inhibitor of activated
STAT1 (PIAS1). Up-regulation of ubiquitin-like specific protease 18 (USP18) in HCV
infection also attenuates JAK-STAT signaling at the receptor level through direct binding to
IFNAR2.
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